{"schema_version":"1.0","type":"article","title":"Boehringer Paid China $358M, Taiwan Got $10M","url":"https://drugnews.com.tw/articles/2026-11-09-boehringer-sino-biopharm-china-licensing-taiwan-gap-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-11-09-boehringer-sino-biopharm-china-licensing-taiwan-gap-en.md","lang":"en","date":"2026-11-09","publish_at":"2026-11-09T08:00:00+08:00","updated_at":"2026-11-09","category":"商業分析系列","topic":"商業分析系列","tags":["licensing deals","Boehringer Ingelheim","Sino Biopharm","ADC","Taiwan biotech"],"summary":"Boehringer Ingelheim paid SBP Group $358M upfront for six preclinical ADC and T-cell engager programs (up to ~$7.36B). Taiwan's nine 2026 out-licensing deals disclosed one upfront, $10M. The gap has two layers: what Taiwan sells, and how much human data it has.","key_points":["On November 4, 2026, Boehringer Ingelheim licensed six preclinical ADC and T-cell engager programs from China's SBP Group for $358 million in upfront and near-term payments, with headline value up to about $7.36 billion.","Taiwan's listed biotechs announced nine out-licensing deals from January to October 2026: six were reformulated drugs or biosimilars, eight covered a single country or region, and the only disclosed upfront was $10 million, so asset structure is the first ceiling.","Eli Lilly paid Korea's ABL Bio $40 million upfront in 2025 and China's Innovent $350 million in February 2026; Evaluate counts 51% of global ADC trials as involving Chinese products, so clinical data scale is the second gate."],"facts":[{"claim":"百靈佳殷格翰與中國生物製藥授權案公告日","value":"2026-11-04","unit":"date","as_of":"2026-11-04","source":"Boehringer Ingelheim 2026-11-04"},{"claim":"百靈佳付給中國生物製藥的首付與近期款項","value":358,"unit":"百萬美元","as_of":"2026-11-04","source":"Boehringer Ingelheim 2026-11-04"},{"claim":"選擇權、開發、法規與銷售里程碑金上限","value":7000,"unit":"百萬美元","as_of":"2026-11-04","source":"Boehringer Ingelheim 2026-11-04"},{"claim":"授權計畫數（ADC 與 T 細胞接合器，臨床前）","value":6,"unit":"個","as_of":"2026-11-04","source":"BioPharm International 2026-11-04"},{"claim":"6 個計畫中授權中國大陸、香港、澳門以外權利者","value":4,"unit":"個","as_of":"2026-11-04","source":"BioPharm International 2026-11-04"},{"claim":"中國生物製藥收購禮新醫藥其餘 95.09% 股權價金上限（2025 年 7 月）","value":951,"unit":"百萬美元","as_of":"2026-11-04","source":"BioPharm International 2026-11-04"},{"claim":"中國對外授權平均首付（Evaluate）2022 年","value":52,"unit":"百萬美元","as_of":"2026-06-16","source":"The Asia Business Daily 2026-06-16"},{"claim":"中國對外授權平均首付（Evaluate）2026 年","value":170,"unit":"百萬美元","as_of":"2026-06-16","source":"The Asia Business Daily 2026-06-16"},{"claim":"韓國 2026 上半年 8 筆技術輸出首付上限","value":"<50","unit":"百萬美元","as_of":"2026-06-16","source":"The Asia Business Daily 2026-06-16"},{"claim":"禮來付給信達生物首付（2026 年 2 月）","value":350,"unit":"百萬美元","as_of":"2026-06-16","source":"The Asia Business Daily 2026-06-16"},{"claim":"台灣上市櫃生技 2026-01-05 至 2026-10-15 公告對外授權筆數","value":9,"unit":"筆","as_of":"2026-11-03","source":"藥時事 台灣生技授權交易總表 2026-11-03"},{"claim":"逸達授權 Primevera 首付","value":10,"unit":"百萬美元","as_of":"2026-01-08","source":"PR Newswire 2026-01-08"},{"claim":"逸達授權 Primevera 里程碑金上限","value":574.5,"unit":"百萬美元","as_of":"2026-01-08","source":"PR Newswire 2026-01-08"},{"claim":"台微體 TLC599 日本授權總額上限","value":203,"unit":"百萬美元","as_of":"2026-10-05","source":"公開資訊觀測站 2026-10-05"},{"claim":"台康生技 EG1206A 日本授權總額","value":1320,"unit":"百萬新台幣","as_of":"2026-06-29","source":"公開資訊觀測站 2026-06-29"},{"claim":"BioNTech 收購普米斯生物首付","value":800,"unit":"百萬美元","as_of":"2024-11-13","source":"BioNTech 2024-11-13"},{"claim":"BioNTech 收購普米斯生物里程碑金上限","value":150,"unit":"百萬美元","as_of":"2024-11-13","source":"BioNTech 2024-11-13"},{"claim":"BMS 付給 BioNTech 的 pumitamig 首付","value":1500,"unit":"百萬美元","as_of":"2025-06-02","source":"BioSpace 2025-06-02"},{"claim":"BMS 至 2028 年前付給 BioNTech 的非條件款","value":2000,"unit":"百萬美元","as_of":"2025-06-02","source":"BioSpace 2025-06-02"},{"claim":"pumitamig 進行中的樞紐試驗數","value":7,"unit":"個","as_of":"2026-11-03","source":"BioNTech 2026-11-03"},{"claim":"禮來付韓國 ABL Bio 平台授權首付（2025 年）","value":40,"unit":"百萬美元","as_of":"2026-06-16","source":"The Asia Business Daily 2026-06-16"},{"claim":"全球 ADC 臨床試驗中來自中國公司產品的比例（Evaluate）","value":51,"unit":"%","as_of":"2026-02-27","source":"Fierce Biotech 2026-02"},{"claim":"全球 CAR-T 臨床試驗中中國的比例（Evaluate）","value":48,"unit":"%","as_of":"2026-02-27","source":"Fierce Biotech 2026-02"}],"sections":["01 | Unpacking $7.36 billion: $358 million comes first","02 | One yardstick: upfront cash in China, Korea and Taiwan","03 | What Taiwan actually sold this year","04 | The second layer: Korea has new platforms and still trails ninefold","05 | Same drug, two sales: who captured the multiple","06 | The counterargument: most of China's numbers will never be paid","07 | Two gates between Taiwan and a comparable upfront","References"],"references":[{"title":"Boehringer Ingelheim and SBP Group enter partnership to advance next-generation cancer therapies","source":"Boehringer Ingelheim","date":"2026-11-04","url":"https://www.boehringer-ingelheim.com/human-health/boehringer-announces-new-oncology-partnership-sbp-group"},{"title":"Boehringer Ingelheim Licenses Six Preclinical ADC and T-Cell Engager Programs From SBP Group in Deal Worth Up to $7 Billion","source":"BioPharm International","date":"2026-11-04","url":"https://www.biopharminternational.com/view/boehringer-ingelheim-licenses-six-preclinical-adc-and-t-cell-engager-programs-from-sbp-group-in-deal-worth-up-to-7-billion"},{"title":"[KR-China Bio Contrast] Despite Similar Promising Technologies, Upfront Payments Are Only One-Third of China's","source":"The Asia Business Daily","date":"2026-06-16","url":"https://view.asiae.co.kr/en/article/2026060908060639753"},{"title":"After 230% deal size explosion, China is no longer the 'bargain basement' for biopharma licensing: analyst (Evaluate's Mark Lansdell","source":"Fierce Biotech","date":"","url":"https://www.fiercebiotech.com/biotech/analyst-china-no-longer-bargain-basement-biotech-acquisitions"},{"title":"BioNTech to Acquire Biotheus","source":"BioNTech (SEC Form 6-K","date":"2024-11-13","url":"https://www.sec.gov/Archives/edgar/data/1776985/000177698524000094/a99_1biontechtoacquirebiot.htm"},{"title":"BMS Commits up to $11B+ To Work With BioNTech on Solid Tumor Bispecific","source":"BioSpace","date":"2025-06-02","url":"https://www.biospace.com/deals/bms-commits-up-to-11b-to-work-with-biontech-on-solid-tumor-bispecific"},{"title":"BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update","source":"BioNTech","date":"2026-11-03","url":"https://www.biontech.com/int/en/home/mediaroom/news/press-releases/2026/11/BioNTech-Announces-Third-Quarter-2026-Financial-Results-and-Corporate-Update.html"},{"title":"Foresee Pharmaceuticals Announces Global Licensing Agreement for MMP-12 Inhibitors with Primevera Therapeutics","source":"PR Newswire","date":"2026-01-08","url":"https://www.prnewswire.co.uk/news-releases/foresee-pharmaceuticals-announces-global-licensing-agreement-for-mmp-12-inhibitors-with-primevera-therapeutics-llc-302656280.html"},{"title":"TLC TLC599 Japan licensing material announcement","source":"MOPS","date":"2026-10-05","url":"https://mops.twse.com.tw/mops/#/web/t05st01?companyId=7924&marketKind=rotc&enterDate=1151005&serialNumber=1"},{"title":"EirGenix EG1206A Japan licensing material announcement","source":"MOPS","date":"2026-06-29","url":"https://mops.twse.com.tw/mops/#/web/t05st01?companyId=6589&marketKind=sii&enterDate=1150629&serialNumber=2"},{"title":"Taiwan biotech licensing tracker","source":"Drugnews","date":"2026-11-03","url":"https://drugnews.com.tw/en/taiwan-licensing-deals.html"}],"images":[{"alt":"Fig. 1 | Of $7.36 billion, $358 million arrives first","url":"https://drugnews.com.tw/assets/articles/boehringer-sino-biopharm-china-licensing-taiwan-gap-en/figure-01.png"},{"alt":"Fig. 2 | One yardstick: upfront payments compared","url":"https://drugnews.com.tw/assets/articles/boehringer-sino-biopharm-china-licensing-taiwan-gap-en/figure-02.png"},{"alt":"Fig. 3 | Taiwan's nine 2026 out-licensing deals: asset type and territory","url":"https://drugnews.com.tw/assets/articles/boehringer-sino-biopharm-china-licensing-taiwan-gap-en/figure-03.png"},{"alt":"Fig. 4 | One drug, two deals","url":"https://drugnews.com.tw/assets/articles/boehringer-sino-biopharm-china-licensing-taiwan-gap-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/boehringer-sino-biopharm-china-licensing-taiwan-gap-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-11-09）。Boehringer Paid China $358M, Taiwan Got $10M。https://drugnews.com.tw/articles/2026-11-09-boehringer-sino-biopharm-china-licensing-taiwan-gap-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/","ai_question":"What changed for On November 4?"}